NCT02990481: A Study of TRK-950 in Patients With Advanced Solid Tumors

NCT02990481
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with symptomatic brain metastases
https://ClinicalTrials.gov/show/NCT02990481

Comments are closed.

Up ↑